SURGICAL resection extent independently determines progression and survival in patients with molecularly defined oligodendrogliomas. In a comprehensive long-term cohort evaluating 240 adult patients with molecularly confirmed isocitrate dehydrogenase mutant and 1p/19q-codeleted tumors, the completeness of initial surgical removal emerged as the single most vital determinant of clinical outcomes. Investigators tracked 149 patients with World Health Organization Grade 2 tumors and 91 patients with Grade 3 tumors to assess whether classic histological grading retains independent prognostic power in the era of definitive molecular classification.
Comparative survival analyses demonstrated that progression-free intervals were strikingly similar between the two histological categories. Patients diagnosed with Grade 2 tumors achieved a median progression-free survival of 57.6 months, which showed no statistically significant difference when compared with the 59.8 months observed in patients with Grade 3 tumors (p = 0.25). Overall survival was remarkably durable across the entire study population, reaching a median of 274 months in the Grade 2 cohort and remaining unreached in the Grade 3 group. Nonetheless, patients presenting with Grade 3 lesions experienced earlier tumor recurrences and a sharper initial downward slope in survival probability, which frequently required the administration of salvage radiotherapy to re-establish clinical disease control.
Multivariate regression analysis confirmed that the extent of surgical resection was the sole independent variable significantly associated with both prolonged progression-free survival (p = 0.026) and extended overall survival (p = 0.016). Importantly, traditional histological grading was not an independent predictor of patient outcomes once researchers controlled for the degree of resection completeness. These findings indicate that while higher grade lesions exhibit an aggressive recurrence pattern requiring diligent post-treatment surveillance, maximizing surgical cytoreduction represents the cornerstone of effective management. For multidisciplinary neuro-oncology teams treating molecularly defined oligodendrogliomas, achieving maximal safe surgical resection remains the most decisive intervention for prolonging progression-free survival and optimizing long-term therapeutic success.
Reference
Bruno F et al. Long-term outcome of molecularly defined oligodendrogliomas: comparison of grade 2 and 3 tumors. Neurology. 2026;107(1):e209876.
Featured Image: showcake on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
